Annual EBITDA
-$127.96 M
-$3.68 M-2.96%
December 31, 2023
Summary
- As of February 26, 2025, CCCC annual EBITDA is -$127.96 million, with the most recent change of -$3.68 million (-2.96%) on December 31, 2023.
- During the last 3 years, CCCC annual EBITDA has fallen by -$63.84 million (-99.58%).
- CCCC annual EBITDA is now -746.52% below its all-time high of -$15.12 million, reached on December 31, 2018.
Performance
CCCC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$24.22 M
-$6.96 M-40.28%
September 30, 2024
Summary
- As of February 26, 2025, CCCC quarterly EBITDA is -$24.22 million, with the most recent change of -$6.96 million (-40.28%) on September 30, 2024.
- Over the past year, CCCC quarterly EBITDA has increased by +$1.20 million (+4.70%).
- CCCC quarterly EBITDA is now -205.86% below its all-time high of -$7.92 million, reached on December 31, 2019.
Performance
CCCC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$103.45 M
+$1.20 M+1.14%
September 30, 2024
Summary
- As of February 26, 2025, CCCC TTM EBITDA is -$103.45 million, with the most recent change of +$1.20 million (+1.14%) on September 30, 2024.
- Over the past year, CCCC TTM EBITDA has increased by +$26.52 million (+20.41%).
- CCCC TTM EBITDA is now -979.87% below its all-time high of -$9.58 million, reached on September 30, 2019.
Performance
CCCC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CCCC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -3.0% | +4.7% | +20.4% |
| 3 y3 years | -99.6% | +4.7% | +20.4% |
| 5 y5 years | -746.5% | +4.7% | +20.4% |
CCCC EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -59.4% | at low | -63.7% | +32.8% | -28.9% | +23.7% |
| 5 y | 5-year | -303.7% | at low | -205.9% | +32.8% | -491.1% | +23.7% |
| alltime | all time | -746.5% | at low | -205.9% | +32.8% | -979.9% | +23.7% |
C4 Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$24.22 M(+40.3%) | -$103.45 M(-1.1%) |
| Jun 2024 | - | -$17.27 M(-38.1%) | -$104.65 M(-14.4%) |
| Mar 2024 | - | -$27.91 M(-18.0%) | -$122.24 M(-4.5%) |
| Dec 2023 | -$127.96 M(+3.0%) | -$34.05 M(+33.9%) | -$127.96 M(-1.6%) |
| Sep 2023 | - | -$25.42 M(-27.1%) | -$129.98 M(-4.1%) |
| Jun 2023 | - | -$34.86 M(+3.7%) | -$135.54 M(+6.6%) |
| Mar 2023 | - | -$33.63 M(-6.7%) | -$127.12 M(+2.3%) |
| Dec 2022 | -$124.28 M(+54.9%) | -$36.06 M(+16.4%) | -$124.28 M(+20.6%) |
| Sep 2022 | - | -$30.99 M(+17.2%) | -$103.02 M(+7.5%) |
| Jun 2022 | - | -$26.44 M(-14.1%) | -$95.84 M(+5.3%) |
| Mar 2022 | - | -$30.79 M(+108.1%) | -$91.06 M(+13.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$80.25 M(+25.2%) | -$14.80 M(-37.9%) | -$80.25 M(-7.2%) |
| Sep 2021 | - | -$23.81 M(+9.9%) | -$86.47 M(+3.3%) |
| Jun 2021 | - | -$21.66 M(+8.4%) | -$83.68 M(+15.5%) |
| Mar 2021 | - | -$19.99 M(-4.9%) | -$72.44 M(+13.0%) |
| Dec 2020 | -$64.11 M(+102.3%) | -$21.01 M(-0.0%) | -$64.11 M(+25.7%) |
| Sep 2020 | - | -$21.02 M(+101.8%) | -$51.02 M(+28.9%) |
| Jun 2020 | - | -$10.42 M(-10.7%) | -$39.58 M(+35.7%) |
| Mar 2020 | - | -$11.66 M(+47.3%) | -$29.16 M(+66.6%) |
| Dec 2019 | -$31.70 M(+109.7%) | -$7.92 M(-17.3%) | -$17.50 M(+82.7%) |
| Sep 2019 | - | -$9.58 M | -$9.58 M |
| Dec 2018 | -$15.12 M | - | - |
FAQ
- What is C4 Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for C4 Therapeutics?
- What is C4 Therapeutics annual EBITDA year-on-year change?
- What is C4 Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for C4 Therapeutics?
- What is C4 Therapeutics quarterly EBITDA year-on-year change?
- What is C4 Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for C4 Therapeutics?
- What is C4 Therapeutics TTM EBITDA year-on-year change?
What is C4 Therapeutics annual EBITDA?
The current annual EBITDA of CCCC is -$127.96 M
What is the all time high annual EBITDA for C4 Therapeutics?
C4 Therapeutics all-time high annual EBITDA is -$15.12 M
What is C4 Therapeutics annual EBITDA year-on-year change?
Over the past year, CCCC annual EBITDA has changed by -$3.68 M (-2.96%)
What is C4 Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CCCC is -$24.22 M
What is the all time high quarterly EBITDA for C4 Therapeutics?
C4 Therapeutics all-time high quarterly EBITDA is -$7.92 M
What is C4 Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CCCC quarterly EBITDA has changed by +$1.20 M (+4.70%)
What is C4 Therapeutics TTM EBITDA?
The current TTM EBITDA of CCCC is -$103.45 M
What is the all time high TTM EBITDA for C4 Therapeutics?
C4 Therapeutics all-time high TTM EBITDA is -$9.58 M
What is C4 Therapeutics TTM EBITDA year-on-year change?
Over the past year, CCCC TTM EBITDA has changed by +$26.52 M (+20.41%)